推动胰腺癌精准医学进展
胰腺导管腺癌(PDAC)诊治数十年面临巨大挑战,发病率和死亡率几乎持平。对PDAC复杂生物学的深入理解提供了更精准治疗的路线图。同源重组修复缺陷和错配修复缺陷的PDAC是临床应识别以进行靶向治疗的亚组。此外,约10%的患者为KRAS野生型PDAC,富集包括融合在内的高度可靶向改变,凸显了整合胚系和体细胞测序的重要性。过去十年的综合测序努力记录了基于基因组和转录组的分类器,后者正作为两种主要亚型——经典型和基底样型——在临床试验中评估。结合靶向KRAS突变及其多效作用的有前景的创新策略,PDAC精准医学的新时代即将到来。
要点
- 临床应识别同源重组修复缺陷和错配修复缺陷的PDAC亚组以进行靶向治疗。
- 约10%的PDAC为KRAS野生型,富集包括融合在内的高度可靶向改变,需整合胚系和体细胞测序。
- 基于转录组的经典型和基底样型两种亚型正在临床试验中评估。
核心结论
- 对PDAC复杂生物学的深入理解提供了更精准治疗的路线图,结合靶向KRAS突变及其多效作用的创新策略,PDAC精准医学新时代即将到来。
主要发现
- 同源重组修复缺陷和错配修复缺陷的PDAC是临床应识别以进行靶向治疗的亚组。
- KRAS野生型PDAC约占10%的患者,富集包括融合在内的高度可靶向改变,凸显整合胚系和体细胞测序的重要性。
- 过去十年的综合测序努力记录了基于基因组和转录组的分类器,转录组分类器正作为经典型和基底样型两种主要亚型在临床试验中评估。
关键数值与推荐
- KRAS野生型PDAC约占10%的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The management of pancreatic ductal adenocarcinoma (PDAC) has posed a considerable challenge for decades, with incidence and mortality rates almost mirroring each other. Despite this, a deeper understanding of the complex biology inherent to PDAC has provided a roadmap for a more precise approach to treatment. PDAC deficient in homologous recombination repair and mismatch repair is a subgroup that should be identified in the clinic for a targeted approach. In addition, KRAS wild-type PDAC, occurring in approximately 10% of patients, is enriched in highly actionable alterations including fusions, underscoring the importance of integrative germline and somatic sequencing. Comprehensive sequencing efforts over the past decade have documented genomic- and transcriptomic-based classifiers, with the latter emerging as two main subtypes: the classical and basal-like, which are now being evaluated in clinical trials. Together with promising, innovative strategies to target KRAS mutations and their pleotropic effects, a new era of precision medicine in PDAC is on the horizon.
引用
- O'Kane GM, Lowery MA. Moving the Needle on Precision Medicine in Pancreatic Cancer. J Clin Oncol. 2022. PMID: 35839440. doi:10.1200/JCO.21.02514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。